{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=41&sponsor=M.D.+Anderson+Cancer+Center",
    "query": {
      "sponsor": "M.D. Anderson Cancer Center",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 3096,
    "total_pages": 310,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=42&sponsor=M.D.+Anderson+Cancer+Center&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=40&sponsor=M.D.+Anderson+Cancer+Center&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T16:02:17.457Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06878144",
      "title": "Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mucormycosis"
      ],
      "interventions": [
        {
          "name": "Mucormycosis",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 300,
      "start_date": "2025-10-20",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-10-16T16:02:17.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06878144"
    },
    {
      "nct_id": "NCT00827801",
      "title": "M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) Symptom Management Program",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heart Failure",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "MDASI-HF Questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2009-01",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2012-07-23",
      "last_synced_at": "2026-10-16T16:02:17.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00827801"
    },
    {
      "nct_id": "NCT00338728",
      "title": "Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Estrogen Receptor Positive",
        "KIT Positive",
        "PDGFR Positive",
        "Postmenopausal",
        "Progesterone Receptor Positive",
        "Prognostic Stage IV Breast Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Imatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 59,
      "start_date": "2003-10-03",
      "completion_date": "2018-11-27",
      "has_results": true,
      "last_update_posted_date": "2020-01-27",
      "last_synced_at": "2026-10-16T16:02:17.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00338728"
    },
    {
      "nct_id": "NCT06906900",
      "title": "A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Spinal Metastasis"
      ],
      "interventions": [
        {
          "name": "TTF-200M and TTF-200A systems",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-08-18",
      "completion_date": "2029-02-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-16T16:02:17.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06906900"
    },
    {
      "nct_id": "NCT02652871",
      "title": "LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "LY2510924",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 36,
      "start_date": "2016-05-09",
      "completion_date": "2019-07-16",
      "has_results": false,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-10-16T16:02:17.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02652871"
    },
    {
      "nct_id": "NCT00890656",
      "title": "Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide (CTX)",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Decadron",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Ara-C",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 90,
      "start_date": "2003-06",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2012-02-20",
      "last_synced_at": "2026-10-16T16:02:17.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00890656"
    },
    {
      "nct_id": "NCT01627067",
      "title": "Exemestane-RAD001-Metformin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 23,
      "start_date": "2012-09",
      "completion_date": "2019-02-01",
      "has_results": true,
      "last_update_posted_date": "2020-06-19",
      "last_synced_at": "2026-10-16T16:02:17.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01627067"
    },
    {
      "nct_id": "NCT06199466",
      "title": "A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "YL-13027",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2024-01-22",
      "completion_date": "2025-09-15",
      "has_results": false,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-10-16T16:02:17.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06199466"
    },
    {
      "nct_id": "NCT07164456",
      "title": "Together Stronger: A Family-centered Lifestyle Intervention for Black Prostate Cancer Survivors and Their Caregivers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Family Centered",
        "Black Ethnicity",
        "Prostate Cancer Survivors"
      ],
      "interventions": [
        {
          "name": "Education sessions",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 648,
      "start_date": "2026-01-13",
      "completion_date": "2033-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-10-16T16:02:17.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07164456"
    },
    {
      "nct_id": "NCT04380545",
      "title": "Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Unresectable Fibrolamellar Carcinoma"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Interferon Alpha 2b-like Protein",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-01-13",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-16T16:02:17.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04380545"
    }
  ]
}